TCT-320 Transcatheter Aortic Valve Replacement with the ACURATE NEO – one year results

Background Preliminary reports on the clinical performance of patients undergoing transcatheter aortic valve replacement (TAVR) with the novel self-expanding ACURATE neo (NEO) (Symetis SA, Eclubens, Switzerland) are promising, however information regarding one-year outcome is lacking. [...]we aimed to assess the clinical outcome using the ACURATE neo in a single-center population according to the updated Valve Academic Research Consortium (VARC-2) criteria. Symptomatic benefit was high with 90% of patients reporting a NYHA class II or less, however 10% of patients were hospitalized due to valve-related symptoms or congestive heart failure.